Fig. 4

In vitro effects of NCL-recognizing F3 peptide-targeted, doxorubicin (DXR)-loaded, pH-sensitive pegylated nanoparticles on NB cell proliferation and viability. A CFSE assay. IMR-32 and SH-SY5Y NB cell lines were treated with 0.5 and 1 μM of both NT-DXR and T-DXR. At 96 h after of treatment, cells were collected and processed by FC to detect CFSE fluorescence. Results are expressed as MFI. Columns: MFI ± S.D. *, p < 0.05, T-DXR 1 μM DXR vs NT-DXR 1 μM DXR; **, p < 0.01 NT-DXR 1 μM DXR vs CTR; ***, p < 0.001, T-DXR 1 μM DXR vs CTR. B Viability assay: NB cells were treated with NT-DXR and T-DXR (0.1–2 μM DXR) and processed to determine cytotoxicity through the MTS assay. Results are expressed as optical density (OD) determined at 490 nm. Columns: OD ± S.D. ***, p < 0.001:T-DXR vs NT-DXR